From Recurrence to Resistance: Real-World Performance of a Hybrid ctDNA Assay in Breast Cancer Management

Penang, Malaysia – At the 14th Asia-Pacific Breast Cancer Summit (APBCS) 2026, Gene Solutions presented real-world data on K-TRACK, a novel hybrid circulating tumor DNA (ctDNA) testing approach. This integrative method, combining tumor-informed and tumor-agnostic approach, addresses a critical gap in precision oncology: the challenge of obtaining high-quality tissue specimens in diverse clinical settings.

Enhanced Pre-Treatment ctDNA Detection

The K-TRACK hybrid methodology combines personalized mutation tracking with a 500-gene hotspot panel to ensure reliable mutation detection regardless of FFPE tissue quality.

In both high-quality and suboptimal samples, the hybrid approach enhanced pre-treatment ctDNA detection, boosting rates by up to 30.3% in low-quality tissues and improving yield by 6.7% even in optimal samples.

ctDNA Strongly Predicts Early Recurrence

In a cohort of 110 early-stage patients, post‑operative ctDNA status was a strong predictor of relapse. Patients with detectable post‑operative ctDNA were significantly more likely to recur.

  • Prognostic Accuracy: The assay demonstrated 80.0% sensitivity and 98.3% specificity in predicting relapse.
  • Lead Time: ctDNA positivity identified recurrence with a maximal lead time of up to 11.0 months before clinical or radiological diagnosis.

These findings support the use of post‑operative ctDNA as a powerful marker of molecular residual disease (MRD), enabling earlier intervention for high‑risk patients.

ctDNA Dynamics Correlate with Treatment Response in Metastatic Breast Cancer

Longitudinal ctDNA monitoring in metastatic disease demonstrated robust alignment with treatment response and disease progression.

  • Progression-Free Survival (PFS) Advantage: Longitudinal monitoring revealed a stark contrast in clinical outcomes; at 12 months, 80.0% of Molecular Responders (MRs) remained progression-free, compared to only 50.0% of Molecular Non-Responders (MnRs).
  • Superior Risk Stratification: K-TRACK assay identified metastatic disease progression with 70.0% sensitivity and 85.7% specificity, revealing that MnRs carry a 6.63-fold higher hazard of progression than responders (HR=6.63).

These results highlight ctDNA as a practical, real‑time indicator of therapeutic efficacy.

Detection of ESR1 Mutations: A Window into Endocrine Resistance

The inclusion of a tumor-agnostic hotspot panel enabled the early detection of ESR1 resistance mutations, found in 12.5% of metastatic ER⁺ patients. Key variants identified included: Y537N (7.1%), Y538G (3.6%), and P535H (1.8%).

The ability to identify emerging ESR1 mutations through serial ctDNA monitoring provides an opportunity for earlier optimization of endocrine therapy.

Conclusion

Across early-stage and metastatic breast cancer populations, the K‑TRACK hybrid ctDNA assay demonstrated strong clinical utility in a real‑world Asian setting by enabling clinicians to:

  • Maximize ctDNA and mutation detection, especially in suboptimal FFPE samples
  • Accurately predict recurrence and monitor treatment response
  • Identify emerging ESR1 resistance mutations for timely therapeutic intervention

These findings underscore the scalability and effectiveness of hybrid ctDNA profiling in modern breast cancer management.

LATEST News

ESMO 2026 Gene Solutions Global Industry Satellite Symposium AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

MADRID, Nov. 18, 2026 — Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company’s evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies span ning cancer screening, precision oncology, and functional applications.     ESMO Congress, one of the world’s leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO’s history. The meeting provided a

Read More
Panel Discussion​ | Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-Omic Liquid Biopsy Implementation Across the Cancer Care Continuum ESMO 2026 Gene Solutions

Inside Gene Solutions’ ESMO 2026 Symposium and Scientific Program: Six Perspectives Across the Cancer Care Continuum

At ESMO Congress 2026 in Madrid, Gene Solutions hosted its first Industry Satellite Symposium at the main ESMO Congress, bringing clinical validation, real-world experience, and multi-omic innovation generated in Asia into the global oncology conversation.  The full-house symposium, “AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation,” brought together six international faculty members to share scientific and clinical perspectives on the future of cancer detection and precision oncology.  Co-chaired by Prof. Umberto Malapelle of the University of Naples Federico II and Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong,

Read More
New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More